Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan's well-defined regulatory framework for cell and regenerative therapies has notched up another "win" with the limited-use approval of a product for knee osteoarthritis, which should also generate useful new revenues for originator Cytori.
You may also be interested in...
Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.